LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-14.59%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$771M
AUM Growth
+$771M
(-20%)
Cap. Flow
-$49M
Cap. Flow
% of AUM
-6.35%
Top 10 Holdings %
Top 10 Hldgs %
57.03%
Holding
73
New
7
Increased
16
Reduced
17
Closed
26
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$44.5M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$24.7M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
$24.1M |
| 4 |
Ascendis Pharma
ASND
|
$20.5M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$17.3M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$4.23B
| $59.4M | 7.71% | 1,615,000 +290,000 | +22% | +$10.7M |
|
2
ALX Oncology
ALXO
$62.7M
| $50.9M | 6.6% | 3,011,352 +105,000 | +4% | +$1.77M |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $45.7M | 5.93% | 900,000 -100,000 | -10% | -$5.08M |
|
4
Design Therapeutics
DSGN
$315M
| $45.2M | 5.86% | 2,797,501 +25,000 | +0.9% | +$404K |
|
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $44.5M | 5.77% | +475,000 | New | +$44.5M |
|
|
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $43.3M | 5.61% | 1,250,000 +500,000 | +67% | +$17.3M |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $43.1M | 5.59% | 340,000 +40,000 | +13% | +$5.07M |
|
|
BCYC
8
Bicycle Therapeutics
BCYC
$511M
| $41.7M | 5.4% | 950,000 +80,000 | +9% | +$3.51M |
|
9
Ventyx Biosciences
VTYX
$171M
| $34.1M | 4.42% | 2,514,280 +690,000 | +38% | +$9.36M |
|
10
IDEAYA Biosciences
IDYA
$2.15B
| $31.9M | 4.13% | 2,850,000 +1,300,000 | +84% | +$14.5M |
|
|
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $30.3M | 3.93% | 1,800,000 +500,000 | +38% | +$8.42M |
|
|
12
Arcutis Biotherapeutics
ARQT
$1.86B
| $28.9M | 3.75% | 1,500,000 +1,250,000 | +500% | +$24.1M |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $28.8M | 3.73% | 350,000 +300,000 | +600% | +$24.7M |
|
14
Kezar Life Sciences
KZR
$28.9M
| $26.8M | 3.48% | 1,614,021 +164,021 | +11% | +$2.73M |
|
|
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $26.5M | 3.44% | 1,385,251 -279,000 | -17% | -$5.34M |
|
16
Dyne Therapeutics
DYN
$1.92B
| $26.4M | 3.42% | 2,734,392 -500,000 | -15% | -$4.82M |
|
17
Fulcrum Therapeutics
FULC
$351M
| $23.7M | 3.07% | 1,000,000 +315,000 | +46% | +$7.45M |
|
|
18
Ascendis Pharma
ASND
$11.8B
| $20.5M | 2.66% | +175,000 | New | +$20.5M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $16.7M | 2.16% | +1,000,000 | New | +$16.7M |
|
20
Olema Pharmaceuticals
OLMA
$375M
| $15.9M | 2.07% | 3,743,875 | – | – |
|
21
Athira Pharma
ATHA
$15.3M
| $9.68M | 1.26% | 717,285 -913,459 | -56% | -$12.3M |
|
|
JNCE
22
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $9.51M | 1.23% | 1,400,000 +50,000 | +4% | +$340K |
|
23
Vera Therapeutics
VERA
$1.38B
| $9.04M | 1.17% | 385,000 +335,000 | +670% | +$7.87M |
|
24
Scholar Rock
SRRK
$3.14B
| $8.7M | 1.13% | +675,000 | New | +$8.7M |
|
25
AnaptysBio
ANAB
$569M
| $7.42M | 0.96% | +300,000 | New | +$7.42M |
|